Phase I dose escalation study of DPPG2-TSL-DOX combined with hyperthermia in soft tissue sarcoma
This is an early research study, called a Phase 1 trial, looking into a new treatment for people with specific types of soft tissue sarcoma. These are cancers that have either spread or can't be removed by surgery. The treatment involves a new drug delivery system, called DPPG2-TSL-DOX, which aims to get the chemotherapy drug directly to the cancer cells. This is used together with heat therapy (hyperthermia), where the tumour area is gently warmed. The main goal is to find the safest dose of this new combination and see if it can help patients. Because this is a very early study, it's the first time this specific treatment is being given to people, so we don't yet know its full effects.
At a glance
What is this study about?
This study is a Phase 1 clinical trial, which means it's one of the first times this new treatment is being tested in humans. The main goal is to find out if the treatment is safe and what the right dose should be. Researchers are looking for any side effects and how the body reacts to the new combination.
The treatment involves two main parts: a special drug called DPPG2-TSL-DOX and heat therapy, also known as hyperthermia. DPPG2-TSL-DOX is designed to deliver chemotherapy directly to cancer cells more effectively, potentially reducing side effects on healthy parts of the body. Hyperthermia involves gently heating the area where the tumour is located, which can make cancer cells more vulnerable to chemotherapy.
This study is for adults who have soft tissue sarcoma that is either advanced (meaning it can't be removed by surgery) or has spread to other parts of the body (metastatic). By combining these two approaches, researchers hope to find a more effective way to treat these types of cancer with fewer overall side effects. It's a crucial step in developing new cancer treatments.
Key takeaways
- This is an early-stage (Phase 1) study for advanced soft tissue sarcoma.
- It tests a new drug delivery method combined with heat treatment.
- The main goal is to find a safe dose and understand side effects.
- Participation is for adults aged 18 and over, of any gender.
- You would receive an experimental treatment, not a placebo.
- It's important to discuss all aspects with your doctor before deciding.
Who may be eligible?
To join this study, you need to be an adult, at least 18 years old. People of any gender can take part.
You would be considered for this study if you have soft tissue sarcoma that is advanced, meaning it cannot be removed by an operation, or if your sarcoma has spread to other parts of your body. The doctors running the study will check if your specific health condition and medical history match certain other requirements to make sure the treatment is safe for you.
There might be other health conditions or medications that would prevent you from joining. This is to ensure your safety throughout the trial. The research team will review all your medical information carefully to see if this study is right for you.
- Are you 18 years old or older?
- Have you been diagnosed with soft tissue sarcoma?
- Is your sarcoma considered advanced (can't be removed by surgery) or has it spread?
- Are you able to attend appointments and follow study instructions?
- Do you feel well enough generally to potentially take part in a study?
- Are you comfortable knowing that this is an early-stage, experimental treatment?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
We do not have detailed information about what taking part in this specific study would involve. However, in a typical Phase 1 study, you would likely have regular visits to the clinic for check-ups, blood tests, and scans. You would receive the study treatment, which in this case involves the DPPG2-TSL-DOX drug and heat therapy. The frequency of treatment and follow-up visits would vary but is often quite frequent in early-stage trials. The total duration of participation usually involves a treatment period followed by ongoing monitoring to see how you are doing, which could last several months or even longer.
Potential risks and benefits
Locations (1)
- —Germany
Common questions
What is soft tissue sarcoma?
Soft tissue sarcoma is a rare type of cancer that forms in the soft tissues of the body, such as muscles, fat, blood vessels, or nerves.
What does 'unresectable' mean?
'Unresectable' means that the cancer cannot be completely removed by surgery, often because of its size or location.
What is hyperthermia?
Hyperthermia is a treatment where the body tissue, or a specific area like a tumour, is heated to a higher temperature. It can sometimes make cancer cells more sensitive to other treatments.
What is a Phase 1 study?
A Phase 1 study is the first step in testing a new treatment in humans. Its main goal is to find a safe dose and look for any serious side effects.
Will I get the new treatment or a placebo?
In most Phase 1 cancer studies, all participants receive the new treatment at different doses because the primary aim is to test safety, not to compare it to an inactive substance (placebo).
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.